Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library-Reference-Cited by-同舟云学术

Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library

Published:2016-10 Issue:43 Volume:291 Page:22496-22508
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Traxlmayr Michael W.,Kiefer Jonathan D.,Srinivas Raja R.,Lobner Elisabeth,Tisdale Alison W.,Mehta Naveen K.,Yang Nicole J.,Tidor Bruce,Wittrup K. Dane

Funder

Austrian Science Fund

Marble Fund of the Koch Institute for Integrative Cancer Research

National Cancer Institute

National Science Foundation

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference46 articles.

1. Engineered protein scaffolds as next-generation antibody therapeutics;Gebauer;Curr. Opin. Chem. Biol,2009

2. High-affinity binders selected from designed ankyrin repeat protein libraries;Binz;Nat. Biotechnol,2004

3. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy;Plückthun;Annu. Rev. Pharmacol. Toxicol,2015

4. DARPins: a new generation of protein therapeutics;Stumpp;Drug Discov. Today,2008

5. Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant—a so-called “anticalin”—using a molecular random approach;Schlehuber;Biophys. Chem,2002

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optical Detection of Interleukin-6 Using Liquid Janus Emulsions Using Hyperthermophilic Affinity Proteins;ACS Omega;2024-08-22

2. Directed-evolution approach to empower EGFR targeting for immunotherapy;Cell Reports Methods;2024-04

3. An engineering strategy to target activated EGFR with CAR T cells;Cell Reports Methods;2024-04

4. Revisiting Protein–Copolymer Binding Mechanisms: Insights beyond the “Lock-and-Key” Model;The Journal of Physical Chemistry Letters;2024-01-16

5. Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies;Current Opinion in Biotechnology;2023-12